Concept Medical Announces Preliminary 3-year Sirona Data At Charing Cross Symposium 2026
· Free Press Journal
Surat: Concept Medical Inc.,announced the presentation of preliminary 3-year follow-up data from the SIRONA randomised trial at the Charing Cross (CX) Symposium 2026, reinforcing its leadership in drug-delivery technologies for peripheral interventions.
Visit rouesnews.click for more information.
The data were presented by Principal Investigator Prof. Ulf Teichgräber during a podium first session on “3-year results from the SIRONA randomised trial.”
Also Watch:
SIRONA is a randomised controlled trial evaluating sirolimus-coated versus paclitaxel-coated balloon angioplasty in femoropopliteal artery disease, designed to generate robust head-to-head comparative evidence in a field historically dominated by paclitaxel-based therapies.
Previously in JACC published 12-month results demonstrated non-inferiority across the trial’s primary efficacy and safety endpoints.
In the current 3-year analysis, MagicTouch PTA, a sirolimus-coated balloon, showed higher freedom from clinically driven target lesion revascularization (cdTLR) compared with the paclitaxel-coated balloon group (88.2% vs 80.2%; HR 0.60; 95% CI 0.36–0.97; log-rank p=0.03).
WATCH: Woman Injured In Nashik Medical College Lift Mishap Dies During Treatment; CCTV Footage Goes ViralThe results are pending Clinical Events Committee (CEC) adjudication. Taken together, these preliminary findings suggest that sirolimus-coated balloon angioplasty may provide more durable long-term outcomes than paclitaxel-coated balloon angioplasty.
At 3 years, Freedom of all-cause mortality remained comparable between treatment groups (92.6% vs 92.6%; HR 1.12; p=0.67), supporting a balanced long-term safety profile. Rates of Freedom of major amputation were low, with no statistically significant difference observed between groups (99.6% vs 99.6%; HR 0.54; p=0.61).
Prof. Ulf Teichgräber, Principal Investigator, said, “The preliminary 3-year SIRONA data are very exciting. Seeing a sustained reduced reduction in cdTLR with MagicTouch PTA over such a long follow-up period is highly encouraging and speaks to the durability of sirolimus-based drug delivery in femoropopliteal interventions.
Assistant Profs Not Being Appointed In Medical Colleges” DME Denies Ban, Yet Posts Remain VacantThese findings add important long-term randomized evidence to the field and, pending final CEC adjudication, represent a very promising signal for the future role of sirolimus-coated balloons in peripheral artery disease.
Importantly, these findings should not be interpreted as a class effect, but rather highlight the need to evaluate individual sirolimus-coated balloon technologies based on robust clinical evidence.”
MP Medical Colleges Neglect Radiation Machines, Wait For Linac Continues; Radiation Machines Functional Only In Indore, JabalpurDr Manish Doshi, Founder and Managing Director, Concept Medical, added: “For us, SIRONA represents the discipline of long-term clinical science, going beyond early outcomes to truly understand durability.
These 3-year findings continue to strengthen the comparative evidence for sirolimus-coated balloon therapy. As we scale globally, our focus remains on generating high-quality, long-term data that clinicians can rely on with confidence.”